Impact of Imatinib Treatment on Renal Function in Chronic
Myeloid Leukemia Patients

J 2022

Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI et. al.

Základní údaje

Originální název

Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients

Autoři

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN (356 Indie, domácí), Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR (203 Česká republika, domácí) a Manju SHARMA

Vydání

Nephrology, Hoboken, Wiley, 2022, 1320-5358

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30217 Urology and nephrology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.500

Kód RIV

RIV/00216224:14110/22:00125092

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/nep.14014

UT WoS

000739713300001

Klíčová slova anglicky

cancer; chronic kidney disease; chronic myeloid leukaemia;imatinib; meta-analysis; tyrosine kinase inhibitors

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 7. 2022 09:20, Mgr. Tereza Miškechová

Anotace

V originále

Background Recently, multiple epidemiological studies have linked imatinib with the alteration of kidney function in chronic myeloid leukemia (CML) patients. This meta-analysis aimed to summarize the impact of Imatinib use on renal function in CML patients. Methods A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature screening, risk of bias, and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the GRADE criteria. Results A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p <0.05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (CKD or AKI) was found to be significantly higher in imatinib users as compared to other TKI (tyrosine kinase inhibitor) users with a pooled relative risk of 2.70 (95% CI: 1.49 – 4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. Conclusion This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.

Návaznosti

EF18_053/0016952, projekt VaV

Název: Postdoc2MUNI

LTC20031, projekt VaV

Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST

Citovat

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR a Manju SHARMA. Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients. Nephrology. Hoboken: Wiley, 2022, roč. 27, č. 4, s. 318-326. ISSN 1320-5358. Dostupné z: https://dx.doi.org/10.1111/nep.14014.

@article{1809822,
   author = {Singh, Avinash Kumar and Hussain, Mohammad Salman and Ahmed, Rayaz and Agrawal, Narendra and Bhurani, Dinesh and Klugar, Miloslav and Sharma, Manju},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1111/nep.14014},
   keywords = {cancer; chronic kidney disease; chronic myeloid leukaemia;imatinib; meta-analysis; tyrosine kinase inhibitors},
   language = {eng},
   issn = {1320-5358},
   journal = {Nephrology},
   title = {Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients},
   url = {https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014},
   volume = {27},
   year = {2022}
}

TY  - JOUR
ID  - 1809822
AU  - Singh, Avinash Kumar - Hussain, Mohammad Salman - Ahmed, Rayaz - Agrawal, Narendra - Bhurani, Dinesh - Klugar, Miloslav - Sharma, Manju
PY  - 2022
TI  - Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients
JF  - Nephrology
VL  - 27
IS  - 4
SP  - 318-326
EP  - 318-326
PB  - Wiley
SN  - 13205358
KW  - cancer
KW  - chronic kidney disease
KW  - chronic myeloid leukaemia;imatinib
KW  - meta-analysis
KW  - tyrosine kinase inhibitors
UR  - https://onlinelibrary.wiley.com/doi/epdf/10.1111/nep.14014
N2  - Background Recently, multiple epidemiological studies have linked imatinib with the alteration of kidney function in chronic myeloid leukemia (CML) patients. This meta-analysis aimed to summarize the impact of Imatinib use on renal function in CML patients. Methods A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Two authors independently performed literature screening, risk of bias, and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the GRADE criteria. Results A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta-analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p <0.05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (CKD or AKI) was found to be significantly higher in imatinib users as compared to other TKI (tyrosine kinase inhibitor) users with a pooled relative risk of 2.70 (95% CI: 1.49 – 4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence. Conclusion This meta-analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.
ER  -

SINGH, Avinash Kumar, Mohammad Salman HUSSAIN, Rayaz AHMED, Narendra AGRAWAL, Dinesh BHURANI, Miloslav KLUGAR a Manju SHARMA. Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukemia Patients. \textit{Nephrology}. Hoboken: Wiley, 2022, roč.~27, č.~4, s.~318-326. ISSN~1320-5358. Dostupné z: https://dx.doi.org/10.1111/nep.14014.

Podrobný výpis o publikaci